Clinical outcomes in breast cancer patients with HIV/AIDS

a retrospective study

Alexandra Gomez, Alberto J. Montero, Judith Hurley

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The purpose of the study is to describe what is the presentation of breast cancer in women with HIV, their tolerance to therapy, the most common complications of treatment and their outcomes. Retrospective chart review of patients with HIV diagnosed with breast cancer between January 1, 1989 and December 31, 2013 at the University of Miami/Jackson Memorial Hospital (UM/JMH) 47 females and 1 male were included in the analysis. The median age of diagnosis was 46 years (IQR 41–52) and 64 % of the women were premenopausal. Median CD4+ count was 330 cells/µL (IQR 131–589 cells/µL). 41 % had AIDS at time of diagnosis. 94 % of patients presented with locoregional disease and 6 % with late stage breast cancer. 52 % had ER+ tumors. 6 % had HER-2/neu tumor expression and 21 % had triple negative disease. The 5 year PFS was 50 % (95 % CI 34–64 %), the 5 year OS was 44 % (95 % CI 29–58 %), and the Breast cancer-specific survival was 57 % (95 % CI 40–70 %). Death was attributed to breast cancer in 22 patients, AIDS progression in 6 patients, other medical condition in 1, and for 4, the cause was unknown. Serious adverse events were documented in 46 % of patients treated with chemotherapy. Targeted therapy was well tolerated. Patients with HIV/AIDS and breast cancer pose a major challenge for oncologists. Surgery, radiation, and endocrine therapy are well tolerated. Standard dose chemotherapy can have life-threatening side effects which can be managed with growth factor support and antimicrobial prophylaxis. All cancer therapy can be given while continuing with antiviral therapy at full dose.

Original languageEnglish
JournalBreast Cancer Research and Treatment
Volume149
Issue number3
DOIs
StatePublished - Feb 13 2015

Fingerprint

Acquired Immunodeficiency Syndrome
Retrospective Studies
HIV
Breast Neoplasms
Drug Therapy
Neoplasms
Therapeutics
CD4 Lymphocyte Count
Antiviral Agents
Intercellular Signaling Peptides and Proteins
Radiotherapy
Survival

Keywords

  • Breast cancer
  • Breast cancer and HIV
  • Chemotherapy complications
  • HIV and cancer
  • HIV infection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical outcomes in breast cancer patients with HIV/AIDS : a retrospective study. / Gomez, Alexandra; Montero, Alberto J.; Hurley, Judith.

In: Breast Cancer Research and Treatment, Vol. 149, No. 3, 13.02.2015.

Research output: Contribution to journalArticle

@article{daef75ecbb034b478abcab61674f0884,
title = "Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study",
abstract = "The purpose of the study is to describe what is the presentation of breast cancer in women with HIV, their tolerance to therapy, the most common complications of treatment and their outcomes. Retrospective chart review of patients with HIV diagnosed with breast cancer between January 1, 1989 and December 31, 2013 at the University of Miami/Jackson Memorial Hospital (UM/JMH) 47 females and 1 male were included in the analysis. The median age of diagnosis was 46 years (IQR 41–52) and 64 {\%} of the women were premenopausal. Median CD4+ count was 330 cells/µL (IQR 131–589 cells/µL). 41 {\%} had AIDS at time of diagnosis. 94 {\%} of patients presented with locoregional disease and 6 {\%} with late stage breast cancer. 52 {\%} had ER+ tumors. 6 {\%} had HER-2/neu tumor expression and 21 {\%} had triple negative disease. The 5 year PFS was 50 {\%} (95 {\%} CI 34–64 {\%}), the 5 year OS was 44 {\%} (95 {\%} CI 29–58 {\%}), and the Breast cancer-specific survival was 57 {\%} (95 {\%} CI 40–70 {\%}). Death was attributed to breast cancer in 22 patients, AIDS progression in 6 patients, other medical condition in 1, and for 4, the cause was unknown. Serious adverse events were documented in 46 {\%} of patients treated with chemotherapy. Targeted therapy was well tolerated. Patients with HIV/AIDS and breast cancer pose a major challenge for oncologists. Surgery, radiation, and endocrine therapy are well tolerated. Standard dose chemotherapy can have life-threatening side effects which can be managed with growth factor support and antimicrobial prophylaxis. All cancer therapy can be given while continuing with antiviral therapy at full dose.",
keywords = "Breast cancer, Breast cancer and HIV, Chemotherapy complications, HIV and cancer, HIV infection",
author = "Alexandra Gomez and Montero, {Alberto J.} and Judith Hurley",
year = "2015",
month = "2",
day = "13",
doi = "10.1007/s10549-015-3275-9",
language = "English",
volume = "149",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Clinical outcomes in breast cancer patients with HIV/AIDS

T2 - a retrospective study

AU - Gomez, Alexandra

AU - Montero, Alberto J.

AU - Hurley, Judith

PY - 2015/2/13

Y1 - 2015/2/13

N2 - The purpose of the study is to describe what is the presentation of breast cancer in women with HIV, their tolerance to therapy, the most common complications of treatment and their outcomes. Retrospective chart review of patients with HIV diagnosed with breast cancer between January 1, 1989 and December 31, 2013 at the University of Miami/Jackson Memorial Hospital (UM/JMH) 47 females and 1 male were included in the analysis. The median age of diagnosis was 46 years (IQR 41–52) and 64 % of the women were premenopausal. Median CD4+ count was 330 cells/µL (IQR 131–589 cells/µL). 41 % had AIDS at time of diagnosis. 94 % of patients presented with locoregional disease and 6 % with late stage breast cancer. 52 % had ER+ tumors. 6 % had HER-2/neu tumor expression and 21 % had triple negative disease. The 5 year PFS was 50 % (95 % CI 34–64 %), the 5 year OS was 44 % (95 % CI 29–58 %), and the Breast cancer-specific survival was 57 % (95 % CI 40–70 %). Death was attributed to breast cancer in 22 patients, AIDS progression in 6 patients, other medical condition in 1, and for 4, the cause was unknown. Serious adverse events were documented in 46 % of patients treated with chemotherapy. Targeted therapy was well tolerated. Patients with HIV/AIDS and breast cancer pose a major challenge for oncologists. Surgery, radiation, and endocrine therapy are well tolerated. Standard dose chemotherapy can have life-threatening side effects which can be managed with growth factor support and antimicrobial prophylaxis. All cancer therapy can be given while continuing with antiviral therapy at full dose.

AB - The purpose of the study is to describe what is the presentation of breast cancer in women with HIV, their tolerance to therapy, the most common complications of treatment and their outcomes. Retrospective chart review of patients with HIV diagnosed with breast cancer between January 1, 1989 and December 31, 2013 at the University of Miami/Jackson Memorial Hospital (UM/JMH) 47 females and 1 male were included in the analysis. The median age of diagnosis was 46 years (IQR 41–52) and 64 % of the women were premenopausal. Median CD4+ count was 330 cells/µL (IQR 131–589 cells/µL). 41 % had AIDS at time of diagnosis. 94 % of patients presented with locoregional disease and 6 % with late stage breast cancer. 52 % had ER+ tumors. 6 % had HER-2/neu tumor expression and 21 % had triple negative disease. The 5 year PFS was 50 % (95 % CI 34–64 %), the 5 year OS was 44 % (95 % CI 29–58 %), and the Breast cancer-specific survival was 57 % (95 % CI 40–70 %). Death was attributed to breast cancer in 22 patients, AIDS progression in 6 patients, other medical condition in 1, and for 4, the cause was unknown. Serious adverse events were documented in 46 % of patients treated with chemotherapy. Targeted therapy was well tolerated. Patients with HIV/AIDS and breast cancer pose a major challenge for oncologists. Surgery, radiation, and endocrine therapy are well tolerated. Standard dose chemotherapy can have life-threatening side effects which can be managed with growth factor support and antimicrobial prophylaxis. All cancer therapy can be given while continuing with antiviral therapy at full dose.

KW - Breast cancer

KW - Breast cancer and HIV

KW - Chemotherapy complications

KW - HIV and cancer

KW - HIV infection

UR - http://www.scopus.com/inward/record.url?scp=84922567326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922567326&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3275-9

DO - 10.1007/s10549-015-3275-9

M3 - Article

VL - 149

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -